Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.65 and traded as low as $3.51. Cryo-Cell International shares last traded at $3.58, with a volume of 7,141 shares traded.

Cryo-Cell International Price Performance

The business has a fifty day moving average price of $3.40 and a 200 day moving average price of $3.65. The company has a market capitalization of $28.85 million, a price-to-earnings ratio of -10.85 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.47) earnings per share for the quarter. The company had revenue of $7.84 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International at the end of the most recent reporting period. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.